The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
A genome-wide association study of more than 2,700 individuals with Crohn's disease uncovered prognosis-related loci distinct from those linked to disease risk.
In Genome Biology this week: 4C-seq to examine chromatin patterns in IBD, Iberian lynx demographic patterns, and more.
In PNAS this week: genetic variants linked to response to food ads, effects of MECP2 mutations in Rett syndrome, and more.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.
Second Genome will work with Kings College researchers to profile infants' skin and gut microbiomes and integrate that information with other omics data collected as part of the study.
In colon tissue samples from individuals with Crohn's disease, researchers discovered either colon- or ileum-like expression features.
Since it was established in 2002, the consortium has identified about 200 previously unknown IBD susceptibility loci.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.